Acne Drugs Market Size, Share & Trends Report

Acne Drugs Market Size, Share & Trends Analysis Report By Type (Inflammatory, Non-inflammatory), By Therapeutic Class, By Mode Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-2-68038-440-6
Number of Report Pages: 100
Format: PDF, Horizon Databook

Historical Range: 2018 - 2022
Forecast Period: 2024 - 2030
Industry: Healthcare

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Acne Drugs Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Acne Drugs Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Acne Drugs Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Acne Drugs Market: Type Movement Analysis, 2023 & 2030 (USD Million)
4.3. Inflammatory Acne
4.3.1. Inflammatory Acne Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Non-inflammatory Acne
4.4.1. Non-inflammatory Acne Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Acne Drugs Market: Therapeutic Class Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Acne Drugs Market: Therapeutic Class Movement Analysis, 2023 & 2030 (USD Million)
5.3. Topical Retinoids
5.3.1. Topical Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Oral Antibiotics
5.4.1. Oral Antibiotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Oral Retinoids
5.5.1. Oral Retinoids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Over the Counter (OTC) Drugs
5.6.1. Over the Counter (OTC) Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Acne Drugs Market: Mode of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Acne Drugs Market: Mode of Administration Movement Analysis, 2023 & 2030 (USD Million)
6.3. Topical
6.3.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Oral
6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Injectable
6.5.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Acne Drugs Market: Distribution Channel Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Acne Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
7.3. Hospital Pharmacies
7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Retail Pharmacies
7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Online Pharmacies
7.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Others
7.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Acne Drugs Market: Regional Estimates & Trend Analysis
8.1. Acne Drugs Market Share, By Region, 2023 & 2030, (USD Million)
8.2. North America
8.2.1. North America Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. UK Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Germany Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. France Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. China
8.4.2.1. China Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Japan Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. India Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. South Korea Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.6. Australia
8.4.6.1. Australia Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Brazil Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.2. Saudi Arabia
8.6.2.1. Saudi Arabia Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. UAE
8.6.3.1. UAE Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. South Africa
8.6.4.1. South Africa Acne Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. GALDERMA
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Recent Developments/ Strategic Initiatives
9.4.2. Johnson & Johnson Services, Inc.
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Recent Developments/ Strategic Initiatives
9.4.3. GSK plc.
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Recent Developments/ Strategic Initiatives
9.4.4. Pfizer Inc.
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Recent Developments/ Strategic Initiatives
9.4.5. AbbVie Inc.
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Recent Developments/ Strategic Initiatives
9.4.6. Sun Pharmaceutical Industries Ltd.
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Recent Developments/ Strategic Initiatives
9.4.7. Bausch Health Companies Inc.
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Recent Developments/ Strategic Initiatives
9.4.8. Nestlé Skin Health S.A.
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Recent Developments/ Strategic Initiatives
9.4.9. Bayer AG
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Recent Developments/ Strategic Initiatives
9.4.10. Viatris Inc.
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Recent Developments/ Strategic Initiatives
9.4.11. Teva Pharmaceutical Industries Ltd.
9.4.11.1. Participant’s Overview
9.4.11.2. Financial Performance
9.4.11.3. Product Benchmarking
9.4.11.4. Recent Developments/ Strategic Initiatives
9.4.12. F. Hoffmann-La Roche Ltd
9.4.12.1. Participant’s Overview
9.4.12.2. Financial Performance
9.4.12.3. Product Benchmarking
9.4.12.4. Recent Developments/ Strategic Initiatives
9.4.13. LEO Pharma A/S
9.4.13.1. Participant’s Overview
9.4.13.2. Financial Performance
9.4.13.3. Product Benchmarking
9.4.13.4. Recent Developments/ Strategic Initiatives
9.4.14. Perrigo Company plc
9.4.14.1. Participant’s Overview
9.4.14.2. Financial Performance
9.4.14.3. Product Benchmarking
9.4.14.4. Recent Developments/ Strategic Initiatives

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.